本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
HO CHI MINH CITY, Vietnam, May 26, 2023 /PRNewswire/ -- Bosch Home Appliances, a premium German brand owned by BSH Vietnam, has officially launched its products in the Vietnamese market. The company introduced an experiential event, named "Bosch: Chuẩn Chất Đức" (Bosch – German quality) to demonstrate its readiness to provide world-class products and services to Vietnamese consumers. Established on January 1st, 2023, BSH Vietnam aims to contribute to the building of a Europe-standard lifestyle in Vietnam through top-quality household appliances and services. During the media launch event, Bosch's products made a lasting impression with their sleek and classy design, along with their highly advanced integrated technologies. The event showcased BSH's commitment to Vietnam, and its ecosystem of authorized products will appeal to mid-end/high-end Vietnamese customers who take an interest in the latest life-improvement trends. Board of Management of BSH Vietnam "We hope our distributors and customers felt Bosch's distinctive German essence shining through at the event. Our true German quality is not just about products with sleek and minimal design that operate with enduring stability, but also in the creation of modern, classy, and creativity-fueled lifestyles. We are confident that brands under BSH will become top European brands in Vietnam in the near future," said BSH Vietnam CEO, Ms Becky Vo. Until now, BSH Vietnam has expanded their distribution network of 1,000 distributor stores selling home appliances across Vietnam, along with official stores on two leading e-commerce sites: Lazada, Shopee, and plan to expand their footprint to all distribution channels in Vietnam in coming time. "As the needs for improving the quality of life of Vietnamese consumers increase, constant competition against other home appliances brands, both domestic and international, is simultaneously an opportunity and a challenge for Bosch when entering Vietnam. Bosch always have Vietnamese consumers' best interests at heart, strive for constant innovation to meet their needs, and provide dedicated post-purchase care," said Mr Oguzkan Akar – Chief Finance Officer of BSH Vietnam. In celebration of the media launch event, customers purchasing Bosch home appliances via the Bosch Home Appliances authorized flagship store on Lazada and Shopee will enjoy the promotion up to 50% for Bosch Home Appliances's products, and three years of warranty coverage along with professional customer care services. About BSH The name Bosch is known worldwide as a symbol of excellent quality and reliability. For more than 85 years now, its home appliances have also honoured this claim: Bosch is Europe's leading household appliances manufacturer. Its products are based exclusively on the real requirements of modern households. Thanks to trendsetting technology and surprisingly simple solutions, they effortlessly achieve perfect results and simplify everyday life. In addition, high quality, precisely finished materials and a timeless, internationally acclaimed design ensure unmistakable quality and sustainability. A recognised high service quality cements the trust of the user in the brand and underpins the Bosch guiding principle, "Invented for life". For more information, visit https://www.bosch-home.com.vn/vi/ Hotline: 1800 8167 (open from 8:00 to 20:00, Monday to Saturday, except on holidays) Facebook page: https://www.facebook.com/BoschHomeVietnamOfficial Community: https://www.facebook.com/groups/congdongboschhomevn Shopee: https://shopee.vn/bosch_home_appliance_2023 Lazada: https://lnkd.in/gh9CivWP
瞻博網路 Beyond Labs將促進與EuroFiber、英特爾、普渡大學和其他客戶、合作夥伴及學術機構在研究、尋路和概念驗證等領域的合作 香港2023年5月26日 /美通社/ -- 提供人工智慧驅動安全網路的領導廠商瞻博網路®（NYSE：JNPR）今天正式發佈了瞻博網路Juniper Beyond Labs。該計畫專注于利用開創性的研究、尋路專案和試驗性技術研發塑造網路和IT行業的未來。瞻博網路Beyond Labs將使用位於森尼韋爾、印度班加羅爾和麻塞諸塞州威斯特福德的創新中心，與學術和行業夥伴開展合作，開創可持續前沿網路技術新局面，滿足數字世界未來的需求。 現在，全球經濟的幾乎每個方面都會以某種方式與網路相連。隨著使用者和設備聯網量的指數級增長，人工智慧、機器學習和雲服務迅猛發展，這種情況只會繼續下去。這創造了大量的機會，但也帶來了基礎設施的複雜性、安全性漏洞和環境挑戰，需要以新的方式部署和管理網路技術，以改善網路使用者和運營商的體驗。瞻博網路Beyond Labs將助力孵化奇思妙想和創新解決方案，以應對全球最棘手的網路技術挑戰。 對於瞻博網路的客戶和合作夥伴，例如Eurofiber（歐洲光纖）和英特爾，以及普渡大學等學術界機構，瞻博網路Beyond Labs將提供影響研究方向和尋路項目的機會。由此產生的成果可推動概念驗證測試演示，並提供回饋，以塑造研究方向。參與成員還將可以使用瞻博網路Beyond Labs的研究和創新成果。例如，瞻博網路將擴大與英特爾的合作，將英特爾FlexRAN參考架構、專用5G網路、瞻博網路無線接入網智慧控制器（RIC）和瞻博網路雲原生路由器（JCNR）與英特爾至強處理器進行整合，啟用新功能以支持5G轉型。 瞻博網路Beyond Labs的研究將關注多個網路領域，包括IT、資料中心、安全、人工智慧/自動化、網路運營、廣域網路和5G/6G，以及正在進行研究的量子計算等新興領域。其中，瞻博網路Beyond Labs將優先考慮把可持續性作為網路設計原則及相關應用的組成部分，以説明網路運營商實現可持續性目標。例如，瞻博網路無線接入網智慧控制器平臺提供了節能功能，例如流量控制，它有助於高效利用網路資源，以滿足容量需求，同時避免額外的資本投資。 瞻博網路Beyond Labs於今天正式推出，而在此之前它已經開發出了榮獲大獎的瞻博網路無線接入網智慧控制器和顛覆性的瞻博網路雲原生路由器，充分利用容器經濟性和運營效率，為服務提供者提供部署5G的靈活性。 相關引言： 「我在心底裡是一名研究者，因此我很高興瞻博網路Beyond Labs將賦予我們新的能力，可以更自由地研究、設計和試驗下一代網路技術，解決行業面臨的巨大挑戰。我們開發的有些解決方案可能會實現商業化，但我們的目的是挑戰各種可能的極限，以滿足不斷發展的數字世界的需求。」 ——Raj Yavatkar，瞻博網路首席技術官 「量子電腦最終將挑戰加密技術，這就是為什麼Eurofiber和瞻博網路在荷蘭推出了量子測試平臺。與瞻博網路Beyond Labs一起，我們正在創新研發一種安全方法，其中使用了量子金鑰分發（QKD）和後量子密碼學（PQC）。」 ——Eric Kuisch，Eurofiber首席運營官 「解決行業挑戰需要從社區層面開始創新。我們與瞻博網路在各種網路計畫方面的合作有助於加速 RAN 生態系統，並在移動運營商中取得切實的業務成果。在加入Beyond Labs後，我們期待繼續深入合作，推動數位世界連接方式的進步。」 ——Dan Rodriguez，英特爾網路和邊緣解決方案事業部公司副總裁 「企業要想讓『即服務』、專用LTE和5G連接產品成為現實，網路自動化是一個關鍵。瞻博網路Beyond Labs可以借助自動化和其他相關企業服務和應用，以期取得進一步的成功。」 ——Will Townsend，Moor Insights＆Strategy副總裁兼首席分析師 「作為普渡大學電腦科學教授，我有幸帶領我的本科生和研究生與瞻博網路合作，這為我們提供了寶貴的見解和知識，讓我們收穫頗豐，深受啟迪。我們很高興有機會通過瞻博網路 Beyond Labs計畫繼續這種合作。」 ——Sonia Fahmy，普渡大學電腦科學教授 其它資源： Beyond Labs頁面 Beyond Labs概況視頻 Beyond Labs信息圖 線上關注瞻博網路：Facebook | Twitter | LinkedIn 瞻博網路博客和社區：J-Net 關於瞻博網路 瞻博網路致力於簡化網路運營並為終端使用者提供卓越的服務體驗。瞻博網路解決方案憑藉領先的行業洞察，同時提供自動化、安全及人工智慧驅動的服務，説明客戶實現真正的業務成果。我們相信，強有力的聯繫能夠穩固合作關係，使我們都有能力面對世界上最大的挑戰——社會福祉、可持續性和平等發展。更多資訊請參見瞻博網路（www.juniper.net）或瞻博網路在Twitter、LinkedIn和Facebook上的主頁。 Juniper Networks、the Juniper Networks標識、Juniper、Junos和在此列出的其他商標是瞻博網路公司在美國和其他國家的注冊商標。其他商標均為其各自所有者的財產。 本新聞稿的資訊可能包含瞻博網路對未來產品、功能或增強功能的開發和計畫（「SOPD 資訊」）。 SOPD 資訊可能隨時更改，恕不另行通知，亦不對任何未來產品、功能、增強或相關規範的交付做任何承諾。在任何情況下，任何購買決定都不應依賴於 SOPD 資訊中列出的時間框架或細節，因為瞻博網路可能會延遲或永遠不會推出未來的產品、功能或增強功能。 任何人在本網站內或從本網站引用或獲得的任何 SOPD 資訊均不會引起與 SOPD 資訊中規定的任何陳述有關或由此引起的針對 Juniper 的任何依賴索賠或任何禁止反言。 瞻博網路不對任何人因 SOPD 資訊中規定的任何陳述而產生的任何損失或損害（無論以何種方式發生）承擔責任。 英特爾、英特爾標識和其他英特爾標誌是英特爾公司或其子公司的商標。
Juniper Beyond Labs will foster collaboration with EuroFiber, Intel, Purdue University and other customers, partners and academic institutions on research, pathfinding and proof-of-concepts. HONG KONG, May 26, 2023 /PRNewswire/ -- Juniper Networks ®, (NYSE: JNPR), a leader in secure, AI-driven networks, today unveiled Juniper Beyond Labs, a new initiative focused on shaping the future of the networking and IT industries with pioneering research, pathfinding projects and experimental technology developments. Juniper Beyond Labs will leverage innovation centers in Sunnyvale, Bengaluru, India and Westford, Massachusetts. Juniper Beyond Labs will collaborate with a community of academic and industry partners with a goal of breaking new ground for sustainable leading edge networking technologies to help meet the future needs of a digital world. Almost every aspect of the global economy now touches the network in some way, and this will only continue as AI, machine learning and cloud services continue to proliferate alongside an exponential increase in connected users and devices. This has created opportunities, but also infrastructure complexities, security vulnerabilities and environmental challenges that require new ways of deploying and managing network technology to improve the experience of network users and operators. Juniper Beyond Labs will help incubate big ideas and innovative solutions to the world's toughest technology challenges. For Juniper customers and partners, such as Eurofiber and Intel, along with the broader academic community like Purdue University, Juniper Beyond Labs will provide an opportunity to influence research directions and pathfinding projects. The resulting contributions could spur proof-of-concept demos and the ability to provide feedback to shape the direction of research. Participating members, will also have access to Juniper Beyond Labs research and innovation developed. As an example, Juniper will be extending its collaboration with Intel and work on the integration of the Intel FlexRAN Reference Architecture, private 5G networks, Juniper RAN Intelligent Controller and the Juniper Cloud-Native Router on Intel Xeon processors, to enable new capabilities to support 5G transformation. Juniper Beyond Labs research will focus on a cross section of networking domains, including IT, Data Center, Security, AI/Automation, Network Operations, WAN and 5G/6G along with emerging areas, like Quantum Computing, where research is ongoing. In particular, Juniper Beyond Labs will prioritize sustainability as an integral part of network design principles and related use cases to help network operators meet sustainability targets. For example, the Juniper RAN Intelligent Controller (RIC) platform today offers energy savings features such as traffic steering that allows efficient utilization of network resources to meet capacity demands while avoiding additional capital investments. While Juniper Beyond Labs is officially launching today, it has already developed the award-winning Juniper RAN Intelligent Controller (RIC) and the disruptive Juniper Cloud-Native Router (JCNR) which takes full advantage of container economics and operational efficiencies to provide service providers flexibility in deploying 5G. Supporting Quotes: "I'm a researcher at heart, so I'm thrilled that Juniper Beyond Labs will give us a newfound ability to research, tinker and experiment more freely with next-generation network technology to solve massive challenges the industry faces. Some of the solutions we develop could become commercially available, but the goal is to push the limits of what we think is possible to meet the needs of an evolving digital world." - Raj Yavatkar, Chief Technology Officer, Juniper Networks "Quantum computers will eventually challenge encryption techniques, which is why Eurofiber and Juniper Networks have launched a Quantum testbed in the Netherlands. Together with Juniper Beyond Labs we are innovating a new security approach, using Quantum Key Distribution (QKD) and Post Quantum Cryptography (PQC)." - Eric Kuisch – Chief Operating Officer, Eurofiber "Working to address industry challenges requires innovation that starts at the community level. Our collaboration with Juniper across network initiatives has helped to accelerate the RAN ecosystem with tangible business outcomes at mobile operators. We look forward to continuing this momentum through our participation in Beyond Labs to advance how the digital world connects." - Dan Rodriguez, CVP Network and Edge Solutions Group, INTEL "Network automation is key to making as-a-service, private LTE & 5G connectivity offerings a reality for enterprises. Juniper's Beyond Labs efforts could position Juniper for success with automation and other adjacent enterprise services and applications." - Will Townsend, VP & Principal Analyst, Moor Insights & Strategy "As a computer science professor at Purdue, I have had the pleasure of collaborating with Juniper with my undergraduate and graduate students. Our engagement with Juniper has been both rewarding and inspiring, providing us with valuable insights and knowledge. We are thrilled to have the opportunity to continue this collaboration through the Juniper Beyond Labs program." - Sonia Fahmy, Professor of Computer Science, Purdue University Additional Resources: Beyond Labs Page Beyond Labs Overview Video Beyond Labs Infographic Follow Juniper Networks online: Facebook | Twitter | LinkedIn Juniper Blogs and Community: J-Net About Juniper Networks Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world's greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook. Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners. The information on this page may contain Juniper's development and plans for future products, features, or enhancements ("SOPD Information"). SOPD Information is subject to change at any time, without notice. Juniper provides no assurances, and assumes no responsibility, that future products, features, or enhancements will be introduced. In no event should any purchase decision be based upon reliance of timeframes or specifics outlined as part of SOPD Information, because Juniper may delay or never introduce the future products, features, or enhancements. Any SOPD Information within, or referenced or obtained from, this website by any person does not give rise to any reliance claim, or any estoppel, against Juniper in connection with, or arising out of, any representations set forth in the SOPD Information. Juniper is not liable for any loss or damage (howsoever incurred) by any person in connection with, or arising out of, any representations set forth in the SOPD Information. Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.
SUZHOU, China, and ROCKVILLE, Md., May 26, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that 4 of its abstracts were selected for presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. These studies report on four of the company's lead drug candidates, including the first and only China-approved third-generation Bcr-Abl inhibitor, olverembatinib (HQP1351), Bcl-2 selective inhibitor, lisaftoclax (APG-2575), MDM2-p53 inhibitor, alrizomadlin (APG-115), and FAK/ALK/ROS1 inhibitor, APG-2449. The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world's most influential and prominent scientific gathering of the clinical oncology community. This year's ASCO Annual Meeting will take place both online and in-person at the McCormick Place, Chicago, IL, United States, on June 2–6, 2023. "We are pleased to have the opportunity to release the updated clinical results on four of our lead drug candidates and showcase our capabilities in global innovation and clinical development at the ASCO Annual Meeting, one of the most prominent medical congresses in the world," said Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma. "Moving forward, we will continue to accelerate these clinical development programs globally in the hope of benefitting more patients around the world as soon as possible." These four clinical studies to be presented at this year's ASCO Annual Meeting are as follows: Drug Candidate Abstract Title Abstract # Format APG-2449 FAK inhibition with novel FAK/ALK inhibitor APG-2449 could overcome resistance in NSCLC patients who are resistant to second-generation ALK inhibitors. #9015 Poster Discussion Olverembatinib (HQP1351) Antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor (TKI)- resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST). #11540 Poster Presentation APG-2575 (Lisaftoclax) Preliminary data of a phase 1b/2 study of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM). #7569 Poster Presentation APG-115 (Alrizomadlin) A phase 2 study of alrizomadlin (APG-115) in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that has failed immuno-oncologic (IO) drugs. #9559 Poster Presentation Poster Discussion APG-2449 FAK inhibition with novel FAK/ALK inhibitor APG-2449 could overcome resistance in NSCLC patients who are resistant to second-generation ALK inhibitors Abstract#: 9015 Poster Board#: 3 Date and Time: June 4, 2023, Sunday, 4:30 PM - 6:00 PM (Central Time) / June 5, 2023, Monday, 5:30 AM - 7:00 AM (Beijing Time) Session Title: Lung Cancer—Non-Small Cell Metastatic Highlights This open-label, multicenter, Phase I dose-escalation and dose-expansion study was designed to evaluate the safety/tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of APG-2449 in patients with ALK/ROS1+ NSCLC or other solid tumors. As of December 9, 2022, 130 patients were enrolled and treated with APG-2449 at doses ranging from 900 to1,500 mg. The median (range) age of these patients was 53 (21-78) years and 53.8% of them were female. After 1,200 mg daily (QD) was determined as the recommended Phase II dose (RP2D), patients with NSCLC were enrolled into 2 dose-expansion cohorts. Among them, Cohort 1 included patients who were resistant to second-generation ALK/ROS1+ tyrosine kinase inhibitors (TKIs), while Cohort 2 included those who were ALK/ROS1+ TKI-naïve. Efficacy Results: In the subgroup of patients with TKI-naïve NSCLC (n = 33; 31 were efficacy evaluable), the overall response rate (ORR) and disease control rate (DCR = complete response [CR] rate + partial response [PR] rate + stable diseases [SD] rate) were 70.6% (12/17) and 88.2% (15/17), respectively, in ROS1+ treatment-naïve patients; and were 78.6% (11/14) and 100% (14/14) in ALK+ treatment-naïve patients. Among the 27 patients with ALK+ NSCLC that was resistant to second-generation ALK inhibitors, 7 achieved PR (7/27; 25.9%) when treated with APG-2449 at the RP2D. Analysis of FAK Expressions: Among the 27 patients with ALK+ NSCLC that was resistant to second-generation ALK inhibitors, compared to baseline, those who experienced PR showed lower phosphorylated FAK (pFAK) levels in peripheral blood mononuclear cells (PBMCs) by Day 28 (24 hours after dosing on Day 28) than patients who experienced SD. Furthermore, patients with progressive disease showed an increase in PBMC pFAK levels on Day 28 compared to baseline, indicating that APG-2449 could inhibit FAK phosphorylation. Meanwhile, patients with higher pFAK expression in tumor tissues at baseline tended to achieve better clinical responses than those with lower pFAK expression after APG-2449 treatment. Safety Results: A total of 117 (90%) patients experienced treatment-related adverse events (TRAEs) with the most frequent TRAEs being elevated blood creatinine (43.8%), elevated alanine aminotransferase (ALT) (40.8%), and aspartate aminotransferase (AST) (33.1%), as well as gastrointestinal disorders that included nausea (25.4%), vomiting (21.5%), and diarrhea (21.5%). A total of 17 (13.1%) TRAEs were grade≥3. Conclusions: APG-2449 showed a favourable preliminary safety profile and antitumor efficacy in patients with NSCLC. Preliminary efficacy was observed in patients who were TKI-naïve and resistant to second-generation ALK inhibitors. FAK inhibition could be a novel approach to overcome ALK resistance in patients with NSCLC that is resistant to second-generation ALK inhibitors. Poster Presentation HQP1351 (Olverembatinib) Antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor- (TKI)- resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST) Abstract#: 11540 Poster Board#: 474 Date and Time: June 3, 2023, Saturday, 1:15 PM – 4:15 PM (Central Time) / June 4, 2022, Sunday, 2:15 AM – 5:15 AM (Beijing Time) Session Title: Sarcoma Highlights This open-label, multicenter Phase Ib/II study in China was designed to evaluate the safety, tolerability, PK, and antitumor activity of olverembatinib in patients with TKI-resistant locally advanced or metastatic GIST. As of January 15, 2023, a total of 20 patients with SDH-deficient GIST were enrolled in the study. The median (range) age of these patients was 30 (14-56) years. Olverembatinib, at doses ranging from 20 to 50 mg (50 mg cohort [n=6]; 40 mg cohort [n=8]; 30 mg cohort [n=6]), was administered once every other day (QOD) in 28-day cycles. Efficacy Results: The median duration of treatment in the 20 patients with SDH-deficient GIST was 7.8 (1.81-42.3) months. A total of 5 of these patients experienced PRs. Of the 16 evaluable patients who were treated with olverembatinib for 16 weeks or more, the clinical benefit rate (CBR=CR+PR+SD > 16 weeks) was 93.8% (15/16) and the longest treatment duration was 42 months. Safety Results: All patients experienced at least one treatment-emergent adverse event (TEAE), most of which were grade 1 or 2; 2 patients experienced grade 3 AEs; and the only hematologic AE with an incidence rate≥20% was anemia (55%). A total of 15 (75%) patients experienced TRAEs, including 1 patient who experienced a grade 3 TRAE (neutropenia). No serious TRAEs were reported during the study. Conclusions: Olverembatinib was well-tolerated up to 50 mg QOD and showed antitumor activity in patients with TKI-resistant SDH-deficient GIST. A total of 5 (25%) PRs were reported among 20 evaluable patients; the 16 patients treated for ≥16 weeks achieved a CBR of 93.8%. These promising findings warrant further investigation. Lisaftoclax (APG-2575) Preliminary data of a phase 1b/2 study of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM). Abstract#: 7569 Poster Board#: 120 Date and Time: June 5, 2023, Monday, 8:00 AM (Central Time) / June 5, 2023, Monday, 9:00 PM (Beijing Time) Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Highlights： This open-label, multicenter, global Phase Ib/II study was designed to evaluate the safety, tolerability, efficacy, and PK of the orally administered high-selective novel Bcl-2 inhibitor lisaftoclax as monotherapy or in combination with ibrutinib or rituximab in patients with WM. As of January 25, 2023, a total of 46 patients were enrolled in the study and later enrolled into 3 arms as follows:Arm A: lisaftoclax monotherapy in patients with WM resistant/intolerant to Bruton tyrosine kinase inhibitors (BTKi) (n=14)Arm B: lisaftoclax plus ibrutinib in treatment-naïve patients (n=24)Arm C: lisaftoclax plus rituximab in ibrutinib and other BTKi-naïve relapsed/refractory patients (n=8)The dose of lisaftoclax was escalated from 400 to 1,200 mg using a modified toxicity probability interval-2 (mTPI-2) design. Doses in Arms A, B, and C were escalated to up to 1,000 mg, 1,200 mg, and 800 mg, respectively. Efficacy Results: The ORR (PR and deeper responses) and median time to response (MTTR) for Arms A, B, and C were 25%, 90.9%, and 37.5%; and 4.3, 1.9, and 4.4 months, respectively. The study did not observe any significant difference between patients with and without the CXCR4 mutation. Safety Results: At 1,200 mg, 1 grade 3 dose-limiting toxicity (DLT) (grade 3 tumor lysis syndrome [TLS]) due to pre-existing renal impairment was observed in Arm B. At 1,000 mg, 1 grade 3 laboratory TLS occurred in Arm B because of dehydration and active symptomatic recurrence. Abnormal electrolytes in this patient was resolved after 1 day of drug intervention and the AE did not recur. Grade≥3 lisaftoclax-related AEs included neutropenia (13%), leukocytopenia (4.3%), anemia (2.2%), weight loss (2.2%), and septic shock (2.2%). Ventricular arrhythmias were not observed. The PK data indicated no drug- drug interaction (DDI) between lisaftoclax and ibrutinib. Conclusions: Lisaftoclax alone or combined with ibrutinib/rituximab demonstrated measurable effects in patients with treatment-naïve or BTKi-refractory WM. Alrizomadlin (APG-115) A phase 2 study of alrizomadlin (APG-115) in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that has failed immuno-oncologic (IO) drugs. Abstract#: 9559 Poster Board#: 322 Date and Time: June 3, 2023, Saturday, 1:15 PM – 4:15 PM (Central Time) / June 4, 2023, Sunday, 2:15 AM – 5:15 AM (Beijing Time) Session Title: Melanoma/Skin Cancers Highlights This open-label, multicenter Phase Ib/II study conducted in the U.S. and Australia was designed to evaluate the safety, tolerability, PK, and antitumor activity of alrizomadlin plus pembrolizumab in patients with unresectable or metastatic cutaneous melanoma or advanced solid tumors. At the meeting, the latest Phase II efficacy and safety results from the cutaneous melanoma subgroup were released. As of December 12, 2022, a total of 31 patients with cutaneous melanoma that had progressed on PD-1/PD-L1 immunotherapy were enrolled in the study. The median (range) age of these patients was 65 (27-84) years, 21 （67.7%）of the patients were male, and 10 (32.3%) were female. Alrizomadlin 150 mg was administered QOD for 2 consecutive weeks, with 1 week off, in 21-day cycles. Pembrolizumab 200 mg was administered intravenously on day 1 of the treatment cycles. Efficacy Results: In 26 efficacy-evaluable patients, 2 achieved CR and, 4 achieved PR, resulting in a confirmed ORR (ORR=CR+PR) of 23.1%. The initial analysis indicated that the ORR observed in patients whose disease had failed IO treatment was primarily attributable to the alrizomadlin plus pembrolizumab regimen, not the delayed effect of prior immunotherapy. Safety Results: A total of 30 (96.8%) patients reported TRAEs, the most frequent (>10%) being nausea (71%), vomiting (38.7%), fatigue (35.5%), thrombocytopenia (32.3%), diarrhea (25.8%), neutropenia (19.4%), decreased appetite (16.1%), and decreased leukocyte count (12.9%). 4 (12.9%) patients reported serious TRAEs, including anemia, thrombocytopenia, deep vein, thrombosis, joint effusion, pulmonary embolism, and vomiting. Conclusions: Alrizomadlin combined with pembrolizumab is well tolerated and demonstrates clinical efficacy in patients with cutaneous melanoma that had progressed on PD-1/PD-L1 immunotherapy.
SINGAPORE, May 26, 2023 /PRNewswire/ -- Plug and Play, a global innovation platform headquartered in Silicon Valley has announced its plans to launch a new office in Kuala Lumpur, Malaysia to support the Future Malaysia Programme by sovereign wealth fund Khazanah Nasional Berhad. Its primary responsibility will be to accelerate the growth of the innovation ecosystem in the country by working with leading corporations and top high-potential startups across the globe through its accelerator programme, which will focus on areas related to Digital Society & Technology Hub, Sustainability & Climate Resilience, and Food Security & Agriculture. These areas are carefully curated to fulfill Malaysia's agenda, build capabilities for the economy, and future-proof several industries present in the country. The Future Malaysia Programme aims to transform technologies via stakeholder involvement that benefits participating startups, corporations, investors, and governments who look to invest and scale emerging technologies in the country. Plug and Play will support this through its accelerator programmes, a platform that leverages its impact through international ties, promoting the attraction and development of tech talent, investments, and more. Startups of all stages from around the globe will be considered to participate and work with the relevant stakeholders to pilot, scale, and commercialise solutions in Malaysia in line with the programme themes. Dato' Amirul Feisal Wan Zahir, Managing Director of Khazanah Nasional Berhad said, "We are pleased to collaborate with Plug and Play to establish a Malaysia-based corporate innovation platform that enables Malaysian corporates to discover and match innovative technology to their business needs. This initiative is in line with our Advancing Malaysia strategy and commitment to delivering sustainable economic and societal benefits for the nation. As corporate innovation is vital for corporates to remain at the forefront of technology trends, we will leverage this platform to create more opportunities for both local and international startups to collaborate with leading Malaysian corporates, pooling resources and expertise to solve real business and innovation challenges and drive potential value creation for both parties. By announcing this collaboration alongside prominent Malaysian corporates, such as CelcomDigi and Sime Darby Plantation, we hope to crowd in more Malaysian corporates to participate in this programme as an all-of-Malaysia approach will be crucial to boosting the local startup ecosystem in Malaysia." "Plug and Play is excited to be part of this new initiative with Khazanah Nasional, CelcomDigi and Sime Darby Plantation as its initial set of partners. With our global presence spanning more than 50 locations and a network of more than 80,000 startups, we are confident that we will be able to identify the world's best top potential startups that will be able to drive their innovative solutions across the thriving innovation landscape in Malaysia. "said Jupe Tan, Managing Partner of Plug and Play APAC. "We look forward to being able to contribute to the growth of the innovation ecosystem in Malaysia in the coming months, as well as setting up our office in Kuala Lumpur." The programme also looks to partner with Malaysia's leading conglomerates to leverage their domain and vertical expertise to pilot, commercialise and invest into emerging technology companies both locally and from across the globe looking to enter and add value to Malaysia. Joining Khazanah Nasional and Plug and Play would be the likes of communications conglomerate CelcomDigi, and the world's largest producer of certified sustainable palm oil, Sime Darby Plantation, with more partners set to come onboard in the coming months. Corporations who join the programme will also be able to explore and match technology and ideas with their innovation needs. The programme also looks to incubate corporate best practices and early-stage investment capabilities for participating corporations. "The Future Malaysia Programme provides CelcomDigi with a unique opportunity to connect with over 80,000 startups in stimulating innovation and synergy between startups and corporates. We are committed to collaborating with other companies and exploring new solutions in areas such as artificial intelligence/machine learning, Web 3.0, digital SME solutions, metaverse, etc. This is further made possible through CelcomDigi's Innovation Centre which is dedicated to exploring and developing innovative technologies, while creating a vibrant ecosystem where startups can thrive and make a meaningful impact. CelcomDigi's focus on innovation and exploration has always pushed us to explore new boundaries and we look forward to playing a significant role in shaping the future of Malaysia's technological landscape," shared T. Kugan, Chief Innovation Officer, CelcomDigi. "Sime Darby Plantation is challenging conventions in an industry that has operated in almost the same way for over a century. When the world shut down three years ago, we realised that the path ahead would be fraught with challenges, unless we changed – our thinking and the way we work. For years, we had set standards, producing the best quality palm oil, produced sustainably and with cutting-edge technology to guide us. Thus, we already had the building blocks in place to develop the plantation of the future. "Today, we have drones and advanced machinery working alongside our people. We use AI and digital data. We use genomics to improve the yields of what is already the most versatile, nutritious, and productive edible oil in the world. We are collaborating with some of the brightest in Universities, at startups, and among young entrepreneurs, both in Malaysia and in other countries to develop automation and robotic solutions. We had imagined a different sort of oil palm plantation and today, we are creating it together with other visionaries. "The Future Malaysia Programme is a tremendous opportunity for us to further explore new technologies and innovations that can strengthen not only our climate resilience and renewable energy initiatives but also our capabilities in digitalisation and robotics. We are truly excited about the prospect of co-innovating with other corporates and new startups to tap into new ideas and synergies that can help us to find solutions. We are committed to working closely with all programme partners to leverage on our collective expertise and deliver meaningful and sustainable results to our business and industry," said Mohamad Helmy Othman Basha, Group Managing Director, Sime Darby Plantation. The Future Malaysia Programme is set to launch in the latter half of 2023, and recruitment is underway for startups and additional new corporate partners. Interested parties who wish to participate in the newly established innovation platform may submit their interest below. Find out more about the Future Malaysia Programme: Click Here About Khazanah Nasional Berhad Khazanah Nasional Berhad ("Khazanah") is the sovereign wealth fund of Malaysia entrusted to deliver sustainable value for Malaysians. In line with its long-term strategy of Advancing Malaysia, Khazanah aims to deliver its purpose by investing in catalytic sectors, creating value through active stewardship, increasing its global presence, as well as building capacity and vibrant communities for the benefit of Malaysians. For more information on Khazanah, visit www.khazanah.com.my. About CelcomDigi Berhad CelcomDigi Berhad (formerly known as "Digi.com Berhad") is Malaysia's largest mobile network operator with more than 20 million users on its network. Established on 1 December 2022, the company aims to serve the growing digital needs of its customers by leveraging its newly combined widest network footprint, distribution touchpoints, innovative range of digital products and services, and superior customer experience powered by over 4,000 top industry experts. The company has clearly defined ambitions to advance the nation, inspire Malaysian society, and be a leader in inclusion and responsible business practices. For more information on CelcomDigi, visit www.celcomdigi.com. About Sime Darby Plantation Berhad Sime Darby Plantation (SDP) is the world's largest producer of Certified Sustainable Palm Oil (CSPO), producing over 2.12 million MT or 14.7% of global CSPO production (as of 31 December 2022). As a fully integrated global plantation company, SDP is involved in various activities along the full spectrum of the palm oil value chain, including upstream and downstream operations, Research & Development, renewables as well as agri-business. Its upstream operations are spread across Malaysia, Indonesia, Papua New Guinea and the Solomon Islands. Its downstream business, also known as Sime Darby Oils, spans 12 countries worldwide and involves the trading, manufacturing, as well as the sales and marketing of refined oils and fats products, oleochemicals, palm oil-based biodiesel, nutraceuticals and other palm oil derivatives. With a workforce of over 80,000 employees and a strong focus on operational excellence, research, innovation and sustainability, Sime Darby Plantation is one of the largest companies on Bursa Malaysia, with a market capitalisation of RM30.08 bil (USD6.51 bil) as of 24 May 2023. About Plug and Play Plug and Play is a global innovation platform. Headquartered in Silicon Valley, we have built accelerator programs, corporate innovation services, and an in-house VC to make technological advancement progress faster than ever before. Since its inception in 2006, our programs have expanded worldwide to include a presence in over 50 locations globally, giving startups the necessary resources to succeed in Silicon Valley and beyond. With over 80,000 startups and over 550 official corporate and government partners, we have created the ultimate startup ecosystem in many industries. We provide active investments with hundreds of leading Silicon Valley VCs and host more than 1,000 networking events per year. Companies in our community have raised over $12 billion in funding, with successful portfolio exits including Danger, Dropbox, Lending Club, and PayPal. Our Asia Pacific headquarters was launched in Singapore in 2010 and we have since expanded into Indonesia, the Philippines and Thailand. Since then we have invested in more than 50 startups and have collaborated with various governments as well as multinational and regional corporations to multiply their innovation efforts through initiatives such as industry-specific accelerator programs. For more information: visit www.plugandplayapac.com
The TORCH-2 study is a Phase I/II trial of the mTORC1/2 inhibitor ATG-008 plus the Anti-PD-1 monoclonal antibody toripalimab for the treatment of patients with advanced solid tumors The combination treatment produced an objective response rate (ORR ) of 52.4% in the advanced cervical cancer cohort (including 75% in PD-L1 positive and 41.7% in PD-L1 negative patients), a disease control rate (DCR) of 90.5% and a median progression-free survival (mPFS) of 7.2 months. SHANGHAI and HONG KONG, May 26, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that the latest results from the Phase I/II TORCH-2 study will be presented as a poster at the 2023 American Society for Clinical Oncology Annual Meeting (ASCO 2023) taking place from June 2nd to 6th, 2023 at the McCormick Place Convention Center in Chicago, IL. Being among the 22 China studies selected for Poster Discussions this year, the abstract will also be presented in a Poster Discussion session on June 3rd. "It is our pleasure to have the latest results from the TORCH-2 study selected for Poster Discussion at ASCO 2023," said Dr. Amily Zhang, Antengene's Chief Medical Officer. "Going forward, we will maintain close collaboration with the investigator team of the TORCH-2 study and liaise with regulatory authorities in China and other APAC markets to align on a registration path in cervical cancer and to continue evaluating the combination in additional ongoing studies in other solid tumors." The TORCH-2 study is a Phase I/II trial of the mTORC1/2 inhibitor ATG-008 plus the Anti-PD-1 monoclonal antibody toripalimab for the treatment of patients with advanced solid tumors. The study enrolled 46 patients, including 21 patients with cervical cancer, to evaluate ATG-008 at three doses (15, 20 and 30 mg) in combination with the standard dose of toripalimab. Study patients had advanced solid tumors with a baseline Eastern Cooperative Oncology Group (ECOG) score of 0-1 (the majority scored 1 on the ECOG scale) and a median of 2 lines of therapy (range:0-7). Median patient age was 53 years. Patients with prior PI3K/AKT/mTOR therapy were excluded. Pharmacokinetics and exploratory biomarkers of drug activity were also evaluated. The data are presented as of the cut-off date of October 21st, 2022. Poster DetailsTitle: A phase I/II study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors Abstract: 2526Session: Developmental Therapeutics – ImmunotherapyPoster: 368Poster Discussion Session Date and Time: 3:00 PM - 4:30 PM, June 3, 2023 (Central Time) / 4:00 AM – 5:30 AM, June 4, 2023 (Beijing Time) 52.4% ORR in the Cervical Cancer Cohort: Among the 21 patients in the cervical cancer cohort, 1 patient with negative PD-L1 expression experienced a CR and 9 patients experienced a partial response (PR). Note that the patient who achieved a CR in this cohort remained on treatment for more than 883 days and is on treatment with single agent ATG-008 as of the cut-off date. The mPFS for the cohort was 7.2 months. Additional Responses in Patients with Nasopharyngeal Carcinoma (NPC): The study reported one additional PR in a patient with NPC; this patient remained on study for over two years. Recommended Phase II Dose (RP2D) was Defined: The RP2D for ATG-008 was determined to be 15 mg in combination with toripalimab. Safety Evaluation Did Not Identify any Dose-Limiting Toxicity (DLT) or Maximum Tolerated Dose (MTD) from the Dose Escalation Phase: The study did not identify any DLT or reach the MTD; 97.8% of patients had more than one treatment emergent adverse event (TEAE) and 69.6% of patients had TEAEs > grade 3, most common of which were decreased lymphocytes (23.9%), rash (10.6%) and hyperglycemia (10.9%). Pharmacokinetic profiles of ATG-008 in combination with toripalimab were similar to ATG-008 monotherapy across APAC and US patients. No new safety signals were reported. About ATG-008 ATG-008 (onatasertib) is an orally available mTORC 1/2 inhibitor. ATG-008 inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, has an important role in the PI3K/AKT/mTOR signaling pathway, which is frequently dysregulated in human cancers. ATG-008 has been studied in clinical trials to treat a broad range of tumor types including multiple myeloma (MM), glioblastoma (GBM), hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), diffuse large B-cell lymphoma (DLBCL), etc. About Antengene Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 29 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland China, Taiwan China, South Korea, Singapore and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2022, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact: Investor Contacts: Donald LungE-mail: Donald.Lung@antengene.com Mobile: +86 18420672158 PR Contacts:Peter QianE-mail: Peter.Qian@antengene.comMobile: +86 13062747000
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
